Parameter | Mean (min.- max.) | Median | n (%) |
---|---|---|---|
Age at treatment (years) | 70 (56–83) | 70 | |
Duration of radiotherapy (weeks) | 7.9 (7.4–8.7) | 7.9 | |
Gleason-Score (n, %) | |||
6 | 4 (14.3 %) | ||
7a (3+4) | 15 (53.6 %) | ||
7b (4+3) | 9 (32.1 %) | ||
cTNM (n, %) | |||
cT1c | 8 (28.6 %) | ||
cT2a | 8 (28.6 %) | ||
cT2b | 3 (10.7 %) | ||
cT2c | 9 (32.1 %) | ||
Neoadjuvant ADT (n, %) | 22 (78.6 %) | ||
Duration of ADT (months, range) | 8.9 (3.0–27.0) | 6.0 | |
Initial PSA peak in ng/ml (range) | 9.1 (1.9–19.8) | 8.3 | |
PSA-peak by subgroup | |||
0 < x ≤ 5 | 3 (10.7 %) | ||
5 < x ≤ 10 | 15 (53.6 %) | ||
10 < x ≤ 15 | 8 (28.6 %) | ||
15 < x ≤ 20 | 2 (7.1 %) |